ClinicalTrials.gg
CompletedNCT02758171Updated Nov 22, 2017Results posted

Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects

A Phase 1 interventional study of Empagliflozin and Linagliptin in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-22.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The primary objective of this trial is to investigate the bioequivalence of one fixed dose combination tablet of empagliflozin/linagliptin (Test, T) compared with the free combination of one empagliflozin tablet and one linagliptin tablet (Reference, R) administered as single dose under fasted conditions.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female subjects according to the investigators assessment, based on a complete medical history including a physical examination, vital signs (Blood Pressure [BP], Pulse Rate [PR]), 12-lead (ECG), and clinical laboratory tests
  • Age of 18 to 55 years (incl.)
  • (BMI) of 18.5 to 29.9 kg/m2 (incl.)
  • Signed and dated written prior to admission to the study in accordance with GCP (Good Clinical Practice) and local legislation
  • Male subjects, or female subjects who meet any of the following criteria starting from at least 30 days before the first administration of trial medication and until 30 days after trial completion:
  • Use of adequate , e.g. any of the following methods plus condom: implants, injectables, combined oral or vaginal contraceptives, intrauterine device
  • Sexually abstinent
  • A vasectomised sexual partner (vasectomy at least 1 year prior to enrolment)
  • Surgically sterilised (including hysterectomy)
  • , defined as at least 1 year of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous levels of FSH (Follicle Stimulating Hormone) above 40 U/L and estradiol below 30 ng/L is confirmatory)

Exclusion criteria

Exclusion criteria:

  • Any finding in the medical examination (including Blood Pressure [BP], Pulse Rate [PR] or [ECG]) is deviating from normal and judged as by the investigator
  • Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 bpm
  • Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  • Any evidence of a concomitant disease judged as clinically relevant by the investigator
  • Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  • Cholecystectomy and/or surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy and simple hernia repair)
  • Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
  • Further exclusion criteria apply
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Empagliflozin+Linagliptin FDC

    One tablet fix dose combination (FDC)

    Drug: Empagliflozin · Drug: Linagliptin

  • Active comparator
    Empagliflozin+Linagliptin single tablets

    Drug: Empagliflozin · Drug: Linagliptin

Interventions

06

What researchers measure

Primary outcomes

  1. AUC0-tz (Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point)

    This outcome measure presents area under the concentration-time curve of Empagliflozin in plasma over the time interval from 0 to the last quantifiable data point. Time frame description: The time -1:00 hour (h) was approximate; the procedure was to be performed and completed within 2h before drug administration. PKS including participants with available data for AUC0-tz (area under the concentration-time curve of Empagliflozin in plasma over the time interval from 0 to the last quantifiable data point).

    Time frame: 1:00 [hour (h): minute] before drug administration and 0:20h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, and 72:00h after drug administration.

  2. AUC0-72 (Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours)

    This outcome measure presents area under the concentration-time curve of Linagliptin in plasma over the time interval from 0 to 72 hours. Time frame description: The time -1:00h was approximate; the procedure was to be performed and completed within 2h before drug administration. PKS including participants with available data for AUC0-72 (area under the concentration-time curve of Linagliptin in plasma over the time interval from 0 to 72 hours).

    Time frame: 1:00 [hour (h): minute] before drug administration and 0:20h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, and 72:00h after drug administration.

  3. Cmax (Maximum Measured Concentration of Empagliflozin Analyte in Plasma)

    This outcome measure presents maximum measured concentration of Empagliflozin analyte in plasma. Time frame description: The time -1:00h was approximate; the procedure was to be performed and completed within 2h before drug administration. PKS including participants with available data for Cmax (maximum measured concentration of Empagliflozin analyte in plasma).

    Time frame: 1:00 [hour (h): minute] before drug administration and 0:20h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, and 72:00h after drug administration.

  4. Cmax (Maximum Measured Concentration of Linagliptin Analyte in Plasma)

    This outcome measure presents maximum measured concentration of Linagliptin analyte in plasma. Time frame description: The time -1:00h was approximate; the procedure was to be performed and completed within 2h before drug administration. PKS including participants with available data for Cmax (maximum measured concentration of Linagliptin analyte in plasma).

    Time frame: 1:00 [hour (h): minute] before drug administration and 0:20h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, and 72:00h after drug administration.

Secondary outcomes

  1. AUC0-infinity (Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 Extrapolated to Infinity)

    This outcome measure presents area under the concentration-time curve of Empagliflozin in plasma over the time interval from 0 extrapolated to infinity. Time frame description: The time -1:00h was approximate; the procedure was to be performed and completed within 2h before drug administration. PKS including participants with available data for AUC0-infinity (area under the concentration-time curve of Empagliflozin in plasma over the time interval from 0 extrapolated to infinity).

    Time frame: 1:00 [hour (h): minute] before drug administration and 0:20h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, and 72:00h after drug administration.

  2. AUC0-infinity (Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 Extrapolated to Infinity)

    This outcome measure presents area under the concentration-time curve of Linagliptin in plasma over the time interval from 0 extrapolated to infinity. Time frame description: The time -1:00h was approximate; the procedure was to be performed and completed within 2h before drug administration. PKS including participants with available data for (area under the concentration-time curve of Linagliptin in plasma over the time interval from 0 extrapolated to infinity).

    Time frame: 1:00 [hour (h): minute] before drug administration and 0:20h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, and 72:00h after drug administration.

07

Results

Posted Nov 22, 2017

Participant flow

Treatment Period 1
Participant flow — Treatment Period 1
MilestoneFDC/Empagliflozin+LinagliptinEmpagliflozin+Linagliptin/FDC
Started2828
Completed2828
Not completed00
Wash-out
Participant flow — Wash-out
MilestoneFDC/Empagliflozin+LinagliptinEmpagliflozin+Linagliptin/FDC
Started2828
Completed2628
Not completed20
Withdrew: Withdrawal by subject10
Withdrew: Other reason10
Treatment Period 2
Participant flow — Treatment Period 2
MilestoneFDC/Empagliflozin+LinagliptinEmpagliflozin+Linagliptin/FDC
Started2628
Completed2628
Not completed00

Outcome measures

PrimaryAUC0-tz (Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point)

This outcome measure presents area under the concentration-time curve of Empagliflozin in plasma over the time interval from 0 to the last quantifiable data point. Time frame description: The time -1:00 hour (h) was approximate; the procedure was to be performed and completed within 2h before drug administration. PKS including participants with available data for AUC0-tz (area under the concentration-time curve of Empagliflozin in plasma over the time interval from 0 to the last quantifiable data point).

Time frame:
1:00 [hour (h): minute] before drug administration and 0:20h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, and 72:00h after drug administration.
Reported as:
Geometric mean · nmol*h/L
AUC0-tz (Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point)
nmol*h/LFDC (10 mg Empagliflozin and 5 mg Linagliptin)Empagliflozin (10 mg) + Linagliptin (5 mg) Single Tablets
AUC0-tz (Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point)2550 ± 18.02510 ± 19.9
Statistical analysis
  • FDC (10 mg Empagliflozin and 5 mg Linagliptin) vs Empagliflozin (10 mg) + Linagliptin (5 mg) Single Tablets · ANOVA · p = <0.0001 · Adjusted geometric mean (gmean) ratio: 101.71 · 90% CI 99.818 to 103.644The ratio \[%\] calculated as T \[FDC (10 mg Empagliflozin and 5 mg Linagliptin)\]/R \[Empagliflozin (10 mg) + Linagliptin (5 mg) Single Tablets\]. Standard deviation is actually intra-individual geometric coefficient of variation (gCV) \[%\].
PrimaryAUC0-72 (Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours)

This outcome measure presents area under the concentration-time curve of Linagliptin in plasma over the time interval from 0 to 72 hours. Time frame description: The time -1:00h was approximate; the procedure was to be performed and completed within 2h before drug administration. PKS including participants with available data for AUC0-72 (area under the concentration-time curve of Linagliptin in plasma over the time interval from 0 to 72 hours).

Time frame:
1:00 [hour (h): minute] before drug administration and 0:20h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, and 72:00h after drug administration.
Reported as:
Geometric mean · nmol*h/L
AUC0-72 (Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours)
nmol*h/LFDC (10 mg Empagliflozin and 5 mg Linagliptin)Empagliflozin (10 mg) + Linagliptin (5 mg) Single Tablets
AUC0-72 (Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 to 72 Hours)281 ± 22.5283 ± 23.3
Statistical analysis
  • FDC (10 mg Empagliflozin and 5 mg Linagliptin) vs Empagliflozin (10 mg) + Linagliptin (5 mg) Single Tablets · ANOVA · p = <0.0001 · Adjusted geometric mean (gmean) ratio: 99.39 · 90% CI 95.290 to 103.672The ratio \[%\] calculated as T \[FDC (10 mg Empagliflozin and 5 mg Linagliptin)\]/R \[Empagliflozin (10 mg) + Linagliptin (5 mg) Single Tablets\]. Standard deviation is actually intra-individual geometric coefficient of variation (gCV) \[%\].
PrimaryCmax (Maximum Measured Concentration of Empagliflozin Analyte in Plasma)

This outcome measure presents maximum measured concentration of Empagliflozin analyte in plasma. Time frame description: The time -1:00h was approximate; the procedure was to be performed and completed within 2h before drug administration. PKS including participants with available data for Cmax (maximum measured concentration of Empagliflozin analyte in plasma).

Time frame:
1:00 [hour (h): minute] before drug administration and 0:20h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, and 72:00h after drug administration.
Reported as:
Geometric mean · nmol/L
Cmax (Maximum Measured Concentration of Empagliflozin Analyte in Plasma)
nmol/LFDC (10 mg Empagliflozin and 5 mg Linagliptin)Empagliflozin (10 mg) + Linagliptin (5 mg) Single Tablets
Cmax (Maximum Measured Concentration of Empagliflozin Analyte in Plasma)370 ± 23.9365 ± 23.9
Statistical analysis
  • FDC (10 mg Empagliflozin and 5 mg Linagliptin) vs Empagliflozin (10 mg) + Linagliptin (5 mg) Single Tablets · ANOVA · p = <0.0001 · Adjusted geometric mean (gmean) ratio: 102.33 · 90% CI 97.945 to 106.910The ratio \[%\] calculated as T \[FDC (10 mg Empagliflozin and 5 mg Linagliptin)\]/R \[Empagliflozin (10 mg) + Linagliptin (5 mg) Single Tablets\]. Standard deviation is actually intra-individual geometric coefficient of variation (gCV) \[%\].
PrimaryCmax (Maximum Measured Concentration of Linagliptin Analyte in Plasma)

This outcome measure presents maximum measured concentration of Linagliptin analyte in plasma. Time frame description: The time -1:00h was approximate; the procedure was to be performed and completed within 2h before drug administration. PKS including participants with available data for Cmax (maximum measured concentration of Linagliptin analyte in plasma).

Time frame:
1:00 [hour (h): minute] before drug administration and 0:20h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, and 72:00h after drug administration.
Reported as:
Geometric mean · nmol/L
Cmax (Maximum Measured Concentration of Linagliptin Analyte in Plasma)
nmol/LFDC (10 mg Empagliflozin and 5 mg Linagliptin)Empagliflozin (10 mg) + Linagliptin (5 mg) Single Tablets
Cmax (Maximum Measured Concentration of Linagliptin Analyte in Plasma)9.33 ± 36.28.73 ± 37.1
Statistical analysis
  • FDC (10 mg Empagliflozin and 5 mg Linagliptin) vs Empagliflozin (10 mg) + Linagliptin (5 mg) Single Tablets · ANOVA · p = 0.0027 · Adjusted geometric mean (gmean) ratio: 107.51 · 90% CI 98.561 to 117.282The ratio \[%\] calculated as T \[FDC (10 mg Empagliflozin and 5 mg Linagliptin)\]/R \[Empagliflozin (10 mg) + Linagliptin (5 mg) Single Tablets\]. Standard deviation is actually intra-individual geometric coefficient of variation (gCV) \[%\].
SecondaryAUC0-infinity (Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 Extrapolated to Infinity)

This outcome measure presents area under the concentration-time curve of Empagliflozin in plasma over the time interval from 0 extrapolated to infinity. Time frame description: The time -1:00h was approximate; the procedure was to be performed and completed within 2h before drug administration. PKS including participants with available data for AUC0-infinity (area under the concentration-time curve of Empagliflozin in plasma over the time interval from 0 extrapolated to infinity).

Time frame:
1:00 [hour (h): minute] before drug administration and 0:20h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, and 72:00h after drug administration.
Reported as:
Geometric mean · nmol*h/L
AUC0-infinity (Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 Extrapolated to Infinity)
nmol*h/LFDC (10 mg Empagliflozin and 5 mg Linagliptin)Empagliflozin (10 mg) + Linagliptin (5 mg) Single Tablets
AUC0-infinity (Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 Extrapolated to Infinity)2580 ± 18.02550 ± 19.8
Statistical analysis
  • FDC (10 mg Empagliflozin and 5 mg Linagliptin) vs Empagliflozin (10 mg) + Linagliptin (5 mg) Single Tablets · ANOVA · Adjusted geometric mean (gmean) ratio: 101.44 · 90% CI 99.574 to 103.336The ratio \[%\] calculated as T \[FDC (10 mg Empagliflozin and 5 mg Linagliptin)\]/R \[Empagliflozin (10 mg) + Linagliptin (5 mg) Single Tablets\]. Standard deviation is actually intra-individual geometric coefficient of variation (gCV) \[%\].
SecondaryAUC0-infinity (Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 Extrapolated to Infinity)

This outcome measure presents area under the concentration-time curve of Linagliptin in plasma over the time interval from 0 extrapolated to infinity. Time frame description: The time -1:00h was approximate; the procedure was to be performed and completed within 2h before drug administration. PKS including participants with available data for (area under the concentration-time curve of Linagliptin in plasma over the time interval from 0 extrapolated to infinity).

Time frame:
1:00 [hour (h): minute] before drug administration and 0:20h, 0:40h, 1:00h, 1:30h, 2:00h, 2:30h, 3:00h, 4:00h, 6:00h, 8:00h, 10:00h, 12:00h, 24:00h, 34:00h, 48:00h, and 72:00h after drug administration.
Reported as:
Geometric mean · nmol*h/L
AUC0-infinity (Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 Extrapolated to Infinity)
nmol*h/LFDC (10 mg Empagliflozin and 5 mg Linagliptin)Empagliflozin (10 mg) + Linagliptin (5 mg) Single Tablets
AUC0-infinity (Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval From 0 Extrapolated to Infinity)451 ± 25.9462 ± 29.2
Statistical analysis
  • FDC (10 mg Empagliflozin and 5 mg Linagliptin) vs Empagliflozin (10 mg) + Linagliptin (5 mg) Single Tablets · ANOVA · Adjusted geometric mean (gmean) ratio: 98.15 · 90% CI 93.456 to 103.082The ratio \[%\] calculated as T \[FDC (10 mg Empagliflozin and 5 mg Linagliptin)\]/R \[Empagliflozin (10 mg) + Linagliptin (5 mg) Single Tablets\]. Standard deviation is actually intra-individual geometric coefficient of variation (gCV) \[%\].

Adverse events

Collected over From first drug administration until 1 day after last drug administration, up to 77 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FDC (10 mg Empagliflozin and 5 mg Linagliptin)—0/56 (0%)8/56 (14.3%)
Empagliflozin (10 mg) + Linagliptin (5 mg) Single Tablets—0/54 (0%)7/54 (13%)
Most frequent other events
Most frequent other events
EventFDC (10 mg Empagliflozin and 5 mg Linagliptin)Empagliflozin (10 mg) + Linagliptin (5 mg) Single Tablets
HeadacheNervous system disorders8/567/54

Baseline characteristics

Treated Set (TS): This subject set included all subjects from the Randomised Set (RS) \[ included all randomised subjects, whether treated or not\] who were documented to have received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(Years)FDC/Empagliflozin+LinagliptinEmpagliflozin+Linagliptin/FDCTotal
Mean39.1 ± 9.738.9 ± 10.239.0 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)FDC/Empagliflozin+LinagliptinEmpagliflozin+Linagliptin/FDCTotal
Female191837
Male91019
08

Study locations

1 site
  • Humanpharmakologisches Zentrum Biberach
    Biberach, 88397, Germany
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2016 to primary completion in Jul 2016, 2 months.

Results were first posted in Nov 2017, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2016
First posted
May 2, 2016
StartActual
May 17, 2016
Primary completionActual
Jul 29, 2016
CompletionActual
Aug 3, 2016
Results first posted
Nov 22, 2017
Last update
Nov 22, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 22, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02758171
Responsible party
Sponsor
First posted
May 2, 2016
Start date
May 17, 2016
Primary completion
Jul 29, 2016
Completion
Aug 3, 2016
Results posted
Nov 22, 2017
Last update
Nov 22, 2017

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Empagliflozin · Linagliptin

Start the discussion